In glioma, ATRX/IDH/p53 combined mutations and individual mutations exhibit opposite effects on the immune microenvironment, which encourages tumor proliferation and invasion (Hu et al., 2022; Hariharan et al., 2024). The gene discussed is TP53; the disease is central nervous system cancer.